<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=ADAMTS1</id>
	<title>ADAMTS1 - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=ADAMTS1"/>
	<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=ADAMTS1&amp;action=history"/>
	<updated>2026-06-08T06:09:38Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.43.6</generator>
	<entry>
		<id>https://transhumanist.ru/index.php?title=ADAMTS1&amp;diff=5812&amp;oldid=prev</id>
		<title>OdysseusBot: Новая страница: «A disintegrin and metalloproteinase with thrombospondin motifs 1 precursor (EC 3.4.24.-) (ADAM-TS 1) (ADAM-TS1) (ADAMTS-1) (METH-1) [KIAA1346] [METH1]  ==Publicat...»</title>
		<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=ADAMTS1&amp;diff=5812&amp;oldid=prev"/>
		<updated>2021-05-12T14:53:50Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «A disintegrin and metalloproteinase with thrombospondin motifs 1 precursor (EC 3.4.24.-) (ADAM-TS 1) (ADAM-TS1) (ADAMTS-1) (METH-1) [KIAA1346] [METH1]  ==Publicat...»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;A disintegrin and metalloproteinase with thrombospondin motifs 1 precursor (EC 3.4.24.-) (ADAM-TS 1) (ADAM-TS1) (ADAMTS-1) (METH-1) [KIAA1346] [METH1]&lt;br /&gt;
&lt;br /&gt;
==Publications==&lt;br /&gt;
&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Increased [[ADAMTS1]] mediates [[SPARC]]-dependent collagen deposition in the aging myocardium.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27143554&lt;br /&gt;
|abstract=Secreted protein acidic and rich in cysteine ([[SPARC]]) is a collagen-binding matricellular protein highly expressed during fibrosis. Fibrosis is a prominent component of cardiac aging that reduces myocardial elasticity. Previously, we reported that [[SPARC]] deletion attenuated myocardial stiffness and collagen deposition in aged mice. To investigate the mechanisms by which [[SPARC]] promotes age-related cardiac fibrosis, we evaluated six groups of mice (n = 5-6/group): young (3-5 mo old), middle-aged (10-12 mo old), and old (18-29 mo old) C57BL/6 wild type (WT) and [[SPARC]]-null (Null) mice. Collagen content, determined by picrosirius red staining, increased in an age-dependent manner in WT but not in Null mice. A disintegrin and metalloproteinase with thrombospondin-like motifs 1 ([[ADAMTS1]]) increased in middle-aged and old WT compared with young, whereas in Null mice only old animals showed increased [[ADAMTS1]] expression. Versican, a substrate of [[ADAMTS1]], decreased with age only in WT. To assess the mechanisms of [[SPARC]]-induced collagen deposition, we stimulated cardiac fibroblasts with [[SPARC]]. [[SPARC]] treatment increased secretion of collagen I and [[ADAMTS1]] (both the 110-kDa latent and 87-kDa active forms) into the conditioned media as well as the cellular expression of transforming growth factor-β1-induced protein (Tgfbi) and phosphorylated Smad2. An [[ADAMTS1]] blocking antibody suppressed the [[SPARC]]-induced collagen I secretion, indicating that [[SPARC]] promoted collagen production directly through [[ADAMTS1]] interaction. In conclusion, [[ADAMTS1]] is an important mediator of [[SPARC]]-regulated cardiac aging.&lt;br /&gt;
|mesh-terms=* ADAMTS1 Protein&lt;br /&gt;
* Aging&lt;br /&gt;
* Animals&lt;br /&gt;
* Cells, Cultured&lt;br /&gt;
* Collagen&lt;br /&gt;
* Extracellular Matrix&lt;br /&gt;
* Extracellular Matrix Proteins&lt;br /&gt;
* Female&lt;br /&gt;
* Fibroblasts&lt;br /&gt;
* Male&lt;br /&gt;
* Mice&lt;br /&gt;
* Mice, Inbred C57BL&lt;br /&gt;
* Mice, Knockout&lt;br /&gt;
* Myocardium&lt;br /&gt;
* Osteonectin&lt;br /&gt;
* Signal Transduction&lt;br /&gt;
* Up-Regulation&lt;br /&gt;
|keywords=* a disintegrin and metalloproteinase with thrombospondin-like motifs 1&lt;br /&gt;
* fibroblast&lt;br /&gt;
* heart&lt;br /&gt;
* matrix metalloproteinase&lt;br /&gt;
* secreted protein acidic and rich in cysteine&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935141&lt;br /&gt;
}}&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=[[ADAMTS9]] is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/20093484&lt;br /&gt;
|abstract=The metalloprotease [[ADAMTS9]] participates in melanoblast development and is a tumor suppressor in esophageal and nasopharyngeal cancer. [[ADAMTS9]] null mice die before gastrulation, but, [[ADAMTS9]] /- mice were initially thought to be normal. However, when congenic with the C57Bl/6 strain, 80% of [[ADAMTS9]] /- mice developed spontaneous corneal neovascularization. beta-Galactosidase staining enabled by a lacZ cassette targeted to the [[ADAMTS9]] locus showed that capillary endothelial cells (ECs) in embryonic and adult tissues and in capillaries growing into heterotopic tumors expressed [[ADAMTS9]]. Heterotopic B.16-[[F10]] melanomas elicited greater vascular induction in [[ADAMTS9]] /- mice than in wild-type littermates, suggesting a potential inhibitory role in tumor angiogenesis. Treatment of cultured human microvascular ECs with [[ADAMTS9]] small-interfering RNA resulted in enhanced filopodial extension, decreased cell adhesion, increased cell migration, and enhanced formation of tube-like structures on Matrigel. Conversely, overexpression of catalytically active, but not inactive, [[ADAMTS9]] in ECs led to fewer tube-like structures, demonstrating that the proteolytic activity of [[ADAMTS9]] was essential. However, unlike the related metalloprotease [[ADAMTS1]], which exerts anti-angiogenic effects by cleavage of thrombospondins and sequestration of vascular endothelial growth factor165, [[ADAMTS9]] neither cleaved thrombospondins 1 and 2, nor bound vascular endothelial growth factor165. Taken together, these data identify [[ADAMTS9]] as a novel, constitutive, endogenous angiogenesis inhibitor that operates cell-autonomously in ECs via molecular mechanisms that are distinct from those used by [[ADAMTS1]].&lt;br /&gt;
|mesh-terms=* ADAM Proteins&lt;br /&gt;
* ADAMTS9 Protein&lt;br /&gt;
* Aging&lt;br /&gt;
* Animals&lt;br /&gt;
* Biocatalysis&lt;br /&gt;
* Cell Movement&lt;br /&gt;
* Corneal Neovascularization&lt;br /&gt;
* Embryo, Mammalian&lt;br /&gt;
* Endothelial Cells&lt;br /&gt;
* Enzyme Activation&lt;br /&gt;
* Gene Knockdown Techniques&lt;br /&gt;
* Humans&lt;br /&gt;
* Mice&lt;br /&gt;
* Mice, Inbred C57BL&lt;br /&gt;
* Microvessels&lt;br /&gt;
* Neoplasm Transplantation&lt;br /&gt;
* Neoplasms&lt;br /&gt;
* Neovascularization, Pathologic&lt;br /&gt;
* Organ Specificity&lt;br /&gt;
* Phosphorylation&lt;br /&gt;
* RNA, Messenger&lt;br /&gt;
* RNA, Small Interfering&lt;br /&gt;
* Receptors, Vascular Endothelial Growth Factor&lt;br /&gt;
* Thrombospondin 1&lt;br /&gt;
* Thrombospondins&lt;br /&gt;
* Vascular Endothelial Growth Factor A&lt;br /&gt;
&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832168&lt;br /&gt;
}}&lt;/div&gt;</summary>
		<author><name>OdysseusBot</name></author>
	</entry>
</feed>